On Cycle Increases In HDL *MAY BE* Associated w/Increase In Fatty Deposits In Artery
IMPORTANT NOTE: I'm not a medical professional of any sort and I have NO background or expertise in this area at ALL. This is NOT medical advice. This isn't intended to be advice at all. I'm providing my OWN PERSONAL NOTES here for educational purposes ONLY. You should consult with a physician and take THEIR advice, not mine.
I wanted to post a follow-up to https://www.reddit.com/r/PEDsR/comments/aeppp8/on_cycle_increases_in_hdl_not_associated/.
A study has just concluded, where HDL function (rather than just "HDL-C") was assessed in AAS users versus non-users. To the best of my knowledge, this is the first such study that looks at HDL function markers in AAS users:
"Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users." https://www.atherosclerosis-journal.com/article/S0021-9150(19)30084-X/fulltext
The results don't look good for AAS users. Here's the short results section of the paper:
"Cholesterol efflux was lower in AASU compared with AASNU and SC (20 vs. 23 vs. 24%, respectively, p < 0.001). However, the lag time for LDL oxidation was higher in AASU compared with AASNU and SC (41 vs 13 vs 11 min, respectively, p < 0.001). We found at least 2 coronary arteries with plaques in 25% of AASU. None of the AASNU and SC had plaques. The time of AAS use was negatively associated with cholesterol efflux."
What's this mean? This means that a measure of HDL function, cholesterol efflux, was worse in the AAS users than in the AAS-non users. The researchers also found plaque in the arteries of the AAS users but not in the AAS-non users. So when HDL-C gets lowered by AAS it may mean an increase in fatty deposits in the AAS-users' arteries.
For some background on HDL function, see https://www.acc.org/latest-in-cardiology/articles/2017/02/01/07/34/quality-over-quantity.